KR20250005053A - Vegf 및 tie2-결합 융합 단백질 및 그의 용도 - Google Patents
Vegf 및 tie2-결합 융합 단백질 및 그의 용도 Download PDFInfo
- Publication number
- KR20250005053A KR20250005053A KR1020247027000A KR20247027000A KR20250005053A KR 20250005053 A KR20250005053 A KR 20250005053A KR 1020247027000 A KR1020247027000 A KR 1020247027000A KR 20247027000 A KR20247027000 A KR 20247027000A KR 20250005053 A KR20250005053 A KR 20250005053A
- Authority
- KR
- South Korea
- Prior art keywords
- identity
- fusion protein
- seq
- vegf
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Cell Biology (AREA)
- Toxicology (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263299177P | 2022-01-13 | 2022-01-13 | |
| US63/299,177 | 2022-01-13 | ||
| US202263310359P | 2022-02-15 | 2022-02-15 | |
| US63/310,359 | 2022-02-15 | ||
| US202263335805P | 2022-04-28 | 2022-04-28 | |
| US63/335,805 | 2022-04-28 | ||
| PCT/US2023/060582 WO2023137395A1 (en) | 2022-01-13 | 2023-01-12 | Vegf and tie2-binding fusion protein and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20250005053A true KR20250005053A (ko) | 2025-01-09 |
Family
ID=87279731
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247027000A Pending KR20250005053A (ko) | 2022-01-13 | 2023-01-12 | Vegf 및 tie2-결합 융합 단백질 및 그의 용도 |
Country Status (16)
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250128899A (ko) * | 2024-02-20 | 2025-08-28 | 주식회사 맵틱스 | Tie2 및 VEGF에 특이적으로 결합하는 이중 특이적 항체 및 이의 용도 |
| WO2026036282A1 (en) * | 2024-08-13 | 2026-02-19 | Pentavision Biosciences Limited | Multispecific fusion proteins targeting angiogenic factors |
| US20260226178A1 (en) * | 2024-12-23 | 2026-08-06 | Ingenia Therapeutics, Inc. | Fusion Proteins Comprising a Tie2 Binding Domain |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3415533A1 (en) * | 2011-08-19 | 2018-12-19 | Regeneron Pharmaceuticals, Inc. | Anti-tie2 antibodies uses thereof |
| JP2020501508A (ja) * | 2016-09-15 | 2020-01-23 | クアドルセプト バイオ リミテッド | 多量体、四量体および八量体 |
| JP2021507723A (ja) * | 2017-12-05 | 2021-02-25 | ユニバーシティ オブ ワシントンUniversity of Washington | 視細胞における治療遺伝子の機能的発現を増強するための組成物および方法 |
| WO2019235856A1 (ko) * | 2018-06-07 | 2019-12-12 | 기초과학연구원 | Tie2에 결합하는 항체 및 이의 용도 |
| EP3805265A4 (en) * | 2018-06-07 | 2022-07-06 | Institute for Basic Science | ANTIBODIES BINDING TO TIE2 AND USES THEREOF |
| JP2021529557A (ja) * | 2018-06-29 | 2021-11-04 | ジェンサン バイオファーマ、 インコーポレイテッドGensun Biopharma, Inc. | 抗腫瘍免疫チェックポイント調節因子アンタゴニスト |
| JP7249060B2 (ja) * | 2018-08-17 | 2023-03-30 | トリカン・バイオテクノロジー・カンパニー・リミテッド | 抗血管新生融合タンパク質およびその使用 |
| EP3856245A4 (en) | 2018-09-24 | 2022-10-26 | EyePoint Pharmaceuticals, Inc. | MULTISPECIFIC ANTIBODIES AGAINST HPTP - BETA (VE-PTP) AND VEGF |
| AU2020385991A1 (en) * | 2019-11-21 | 2022-06-23 | Unity Biotechnology | Antibodies directed to Tie-2 and methods of use |
| CA3169967A1 (en) * | 2020-03-24 | 2021-09-30 | Genentech, Inc. | Tie2-binding agents and methods of use |
-
2023
- 2023-01-12 AU AU2023206363A patent/AU2023206363A1/en active Pending
- 2023-01-12 JP JP2024542028A patent/JP7884072B2/ja active Active
- 2023-01-12 EP EP23740846.3A patent/EP4463482A4/en active Pending
- 2023-01-12 WO PCT/US2023/060582 patent/WO2023137395A1/en not_active Ceased
- 2023-01-12 MX MX2024008737A patent/MX2024008737A/es unknown
- 2023-01-12 PE PE2024001601A patent/PE20260003A1/es unknown
- 2023-01-12 US US18/153,965 patent/US20230287109A1/en active Pending
- 2023-01-12 CR CR20240342A patent/CR20240342A/es unknown
- 2023-01-12 GE GEAP202416581A patent/GEAP202416581A/en unknown
- 2023-01-12 CA CA3242904A patent/CA3242904A1/en active Pending
- 2023-01-12 KR KR1020247027000A patent/KR20250005053A/ko active Pending
- 2023-01-12 IL IL314219A patent/IL314219A/en unknown
-
2024
- 2024-07-11 CL CL2024002106A patent/CL2024002106A1/es unknown
- 2024-07-12 DO DO2024000136A patent/DOP2024000136A/es unknown
- 2024-07-14 JO JOJO/P/2024/0158A patent/JOP20240158A1/ar unknown
- 2024-08-12 CO CONC2024/0010934A patent/CO2024010934A2/es unknown
-
2025
- 2025-08-18 CL CL2025002473A patent/CL2025002473A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL314219A (en) | 2024-09-01 |
| GEAP202416581A (en) | 2024-12-10 |
| JP7884072B2 (ja) | 2026-07-02 |
| WO2023137395A1 (en) | 2023-07-20 |
| DOP2024000136A (es) | 2024-10-15 |
| AU2023206363A1 (en) | 2024-08-15 |
| CL2025002473A1 (es) | 2025-11-14 |
| MX2024008737A (es) | 2024-09-11 |
| US20230287109A1 (en) | 2023-09-14 |
| JOP20240158A1 (ar) | 2024-07-14 |
| CA3242904A1 (en) | 2025-03-14 |
| JP2025503704A (ja) | 2025-02-04 |
| EP4463482A1 (en) | 2024-11-20 |
| CL2024002106A1 (es) | 2025-03-28 |
| EP4463482A4 (en) | 2026-05-06 |
| CR20240342A (es) | 2024-09-18 |
| PE20260003A1 (es) | 2026-01-06 |
| CO2024010934A2 (es) | 2024-10-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7314356B2 (ja) | 改変j鎖を有する結合分子 | |
| KR102962557B1 (ko) | 새로운 il-15 프로드럭 및 이를 사용하는 방법 | |
| US20250051413A1 (en) | Chimeric molecules comprising il-12 agonist polypeptide | |
| JP6783797B2 (ja) | 抗がん融合ポリペプチド | |
| EP3733715A1 (en) | Triabody, preparation method and use thereof | |
| JP7102670B2 (ja) | 抗pd‐l1抗体とil‐7との融合 | |
| US20230287109A1 (en) | VEGF and TIE2-Binding Fusion Protein and Uses Thereof | |
| US9815893B2 (en) | Anti-VEGF antibodies and their uses | |
| CN112534052A (zh) | 全新il-21前药及使用方法 | |
| TW202012440A (zh) | 包含4-1bbl之靶向her2的抗原結合分子 | |
| JP2021500902A (ja) | 新規tnfファミリーリガンド三量体含有抗原結合分子 | |
| WO2019080872A1 (zh) | 阻断pd-1/pd-l1信号传导途径且活化t细胞的融合蛋白及其用途 | |
| KR20100128291A (ko) | Egfr에 결합하는 조작된 단백질을 기초로 하는 표적화된 치료제 | |
| TW202134277A (zh) | N—端scFv多特異性結合分子 | |
| CN115925977B (zh) | 双特异性融合多肽及其应用 | |
| TW201609805A (zh) | 結合egfr及met之多功能抗體 | |
| KR20220007086A (ko) | T1dm 및 췌도염의 치료에 사용하기 위한 항-cd40 항체 | |
| JP7270944B1 (ja) | 抗cadm1抗体またはその抗原結合断片 | |
| EP4559932A1 (en) | Multispecific antibody and use thereof | |
| KR20250135302A (ko) | 항-cmet 항체 및 사용 방법 | |
| JP2026500752A (ja) | 抗b7h3抗体及びその使用方法 | |
| KR20140025836A (ko) | 항 HER2/Neu 단일클론항체와 IL-7가 연결된 융합 단일클론 항체 및 이를 포함하는 암 치료용 조성물 | |
| TW202428608A (zh) | 抗b7h3抗體以及其使用方法 | |
| JP2025532652A (ja) | Cd137およびcd228に特異的な新規融合タンパク質 | |
| HK40118737A (en) | Vegf and tie2-binding fusion protein and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P12 | Request for amendment of application rejected |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P12-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P12-X000 | Request for amendment of application rejected |
St.27 status event code: A-2-2-P10-P12-nap-X000 |